PDCD1 and colorectal cancer: Additional candidates identified by scDrug include rapamycin, an mTOR inhibitor that has been reported to enhance anti-PD-1 efficacy in colorectal cancer models [127] and has been investigated clinically for its efficacy in combination with anti-PD-1 (Table 1).